CLDN1 and prostate cancer: Loss of CLDN1 has been reported to stimulate the tumor progression and invasion in some cancers, including prostate cancer, breast cancer and melanocytic neoplasia, while in esophageal squamous cell carcinoma, increased expression of CLDN1 was correlated with tumor progression [19–22].